Dominik Ruettinger

Global Head Research and Early Development Oncology at Bayer

Speaker

Prof. Ruettinger is Global Head of Research and Early Development for Oncology at Bayer, with more than two decades of experience in oncology drug discovery and development. He joined Bayer in 2021 from Roche/Genentech, where he was Head of Oncology, Pharma Research and Early Development. Before joining Roche in 2011, he was with Micromet Inc. (acquired by Amgen Inc. in 2012), where he led various clinical development programs of the BiTE (bispecific T-cell engagers) platform, an effort that led to the approval of Blinatumumab (BlincytoTM), the first ever approval of a CD19-directed T-cell bispecific in 2014. Recently, another molecule for which Dominik had led the early development, received global approval: Glofitamab (ColumviTM), the first fixed treatment duration CD20xCD3 T-cell bispecific. Throughout his career, Dominik led search and evaluation for novel drug development candidates, technologies, and the most innovative newcos, leading to numerous in-licensing deals, M&As as well as collaborations. Dominik has spent 12 years in academia in Germany and the U.S., is board certified in surgical oncology and holds a Ph.D. degree in tumor immunology from the University of Munich, Germany, where he still teaches and holds a faculty position.